TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Shingles Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 60 years of age and older.~* History of Chickenpox.~* Have given written informed consent prior to enrollment.~* History of varicella or long-term (greater than or equal to 30 years) residence in the continental USA.~Exclusion Criteria:~* No history of shingles, no current history of immune suppression (e.g. malignancy or neoplastic disease, corticosteroid therapy).~* No immunosuppression resulting from disease (e.g., malignancy; HIV infection), corticosteroids (except intermittent topical or inhaled corticosteroid \[greater than 800 mcg/day beclomethasone dipropionate or equivalent\]), or other immunosuppressive/cytotoxic therapy (cancer chemotherapy or organ transplantation).~* No active neoplastic disease (except local skin cancer or other malignancies \[e.g., prostate cancer\] that are stable in the absence of immunosuppressive/cytotoxic therapy).~* No prior Herpes Zoster.~* No prior receipt of varicella vaccine.~* No allergic sensitivity to neomycin.~* No history of anaphylactoid reaction to gelatin.~* No significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 5 years).~* Not ambulatory (must not be bed-ridden or homebound).~* No receipt of immune globulin or any other blood product within 3 months before or planned during the 3-5 year study period.~* No receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products \[e.g., dT, pneumococcal vaccine, hepatitis A vaccine, hepatitis B vaccine\]), or scheduled within 6 weeks after study vaccination.~* Not currently receiving antiviral therapy.~* No other condition (e.g., extensive psoriasis, chronic pain syndrome, cognitive impairment, severe hearing loss) that, in the opinion of the investigator, might interfere with the evaluations required by the study.~* No intercurrent illness (e.g., urinary tract infection, influenza) that might interfere with the interpretation of the study.~* No females who are pre-menopausal.~* No subjects unlikely to adhere to protocol follow-up.~* No subjects involved in a conflicting (vaccine or investigational drug) clinical trial.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): varicella-zoster vaccine
- Arm 2 (Type: PLACEBO_COMPARATOR): vaccine placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Energy Density Over 5 Days in Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Attending one of the designated daycare centers~Exclusion Criteria:~* Food Allergies~* Food restrictions~* Health Issues that Preclude Participation~* Not available for duration of the study

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- 100% Food Energy Density (Type: EXPERIMENTAL): Baseline Food Energy Density
- 80% Food Energy Density (Type: EXPERIMENTAL): Lower Food Energy Density
- 120% Food Energy Density (Type: EXPERIMENTAL): Higher Food Energy Density

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Diclofenac Capsules to Treat Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 50 years of age~* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~* Patient requires extraction of 2 or more third molars~* Patient must be willing to stay at the study site overnight~Exclusion Criteria:~* Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs~* Patient has a current disease or history of a disease that will impact the study or the patient's well-being~* Patient has used or intends to use any of the medications that are prohibited by the protocol~* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test~* Patient has taken another investigational drug within 30 days prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac Test (lower dose) (Type: EXPERIMENTAL): One 18-mg Diclofenac Test Capsule and 1 placebo capsule
- Diclofenac Test (upper dose) (Type: EXPERIMENTAL): One 35-mg Diclofenac Test Capsule and 1 placebo capsule
- Celecoxib 400 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Clinical Trial of the Evera MRI System for Conditionally-safe MRI Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are indicated for implantation of an ICD at the time of study enrollment.~* Subjects who are able to undergo a pectoral implant.~* Subjects who are receiving an ICD for the first time.~* Subjects who are able and willing to undergo elective MRI scanning without sedation.~* Subjects who are geographically stable and available for follow-up at the study site for the length of the study.~* Subjects who are at least 18 years of age (or older, if required by local law).~Exclusion Criteria:~* Subjects with a history of significant tricuspid valvular disease .~* Subjects for whom a single dose of 1.0mg dexamethasone sodium phosphate and/or dexamethasone acetate may be contraindicated.~* Subjects who require a legally authorized representative to obtain informed consent.~* Subjects undergoing device upgrades, change-outs, lead extractions, and/or lead or device revisions.~* Subjects with abandoned or capped leads.~* Subjects who require an indicated MRI scan, other than those specifically described in the Evera MRI™ study, before the one-month post-MRI/waiting period follow-up (approximately 4 months post-implant).~* Subjects with a non-MRI compatible device (such as neurostimulators) or material implant (e.g., non-MRI compatible sternal wires, neurostimulators, biostimulators, metals or alloys).~* Subjects with medical conditions that preclude the testing required by the study protocol or limit study participation.~* Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the Evera MRI™ study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.~* Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy test within seven (7) days prior to device implant.~* Subjects with exclusion criteria required by local law (e.g., age, breastfeeding).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI Group (Type: EXPERIMENTAL): Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
- Control Group (Type: SHAM_COMPARATOR): Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* allergic rhinitis and/or~* mild stable asthma~* house dust mite allergic~* positive HDM-specific IgE as determined by skin prick test (wheal diameter \>6 mm to D. pteronyssinus) or CAP-Pharmacia score \> 2~Exclusion Criteria:~* Immunodeficiency diseases~* Severe or uncontrolled asthma~* Previous immunotherapy with House dust mite (HDM) extract within the last five years or ongoing immunotherapy with HDM or other allergens~* Continuous oral corticosteroids~* Subjects on treatment with beta-blockers~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Matching placebo- control arm (first year)
- 2 (Type: ACTIVE_COMPARATOR): Drug Staloral (active group)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients 18 years of age or older~* Male or female patients are eligible~* For newly diagnosed/untreated patients with essential hypertension defined as msDBP ≥ 90 and \< 110 mmHg at Visit 1 and Visit 4~* For previously treated patients with essential hypertension defined as msDBP ≥ 90 and \< 110 mmHg after 2 to 4 weeks of washout (Visit 4)~Exclusion Criteria:~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of Hypertensive encephalopathy or cerebrovascular accident.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren/Amlodipine (Type: EXPERIMENTAL): None
- Aliskiren/Amlodipine/HCTZ (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men and women aged 18 to 55 years. Healthy as determined by the investigator on the basis of medical history and physical examination, laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).~* History of being a nonsmoker for at least 1 year.~* Subjects have to be either extensive CYP2D6 metabolizers with a normal complement of 1 or 2 fully active enzyme gene alleles or poor CYP2D6 metabolizers (lack of active enzyme gene alleles) via genetic testing of a blood sample.~Exclusion Criteria:~* Presence or history of any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease or any severe conditions of the ears, eyes or throat (such as glaucoma or increased intraocular pressure).~* Known or suspected alcohol abuse or consumption of more than 2 standard units per day (a standard unit equals 12 ounces of beer, 1½ ounces of 80-proof alcohol, or 6 ounces of wine) within the past 6 months.~* Known or suspected current abuse of prohibited drugs or other substances. Use of any hormonal therapy within 30 days before study day -1 until the end of the partial inpatient confinement period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- DVS/VEN (Type: ACTIVE_COMPARATOR): None
- VEN/DVS (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Both man and woman who is over 19years old.~* Hypertension with primary cholesterolemia and satisfy the lab results that Mean msSBP is under 180mmHg and Mean msDBP is under 110mmHg and LDL-C is 250mg/DL or under and Triglycerides is under 400mg/dL~Exclusion Criteria:~* Therapeutic lifestylechange is not enought during the study period~* SBP difference is bigger than 20mmHg or DBP difference is bigger than 10mmHg at screening visit

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CR group (Type: EXPERIMENTAL): DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
- CP group (Type: ACTIVE_COMPARATOR): DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
- PR group (Type: ACTIVE_COMPARATOR): DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Facemask Use During High-intensity Interval Exercise in Temperate and Hot Environments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older and, are able to both speak and read in English.~* Physically active and used to high-intensity exercise.~* No known serious medical conditions.~Exclusion Criteria:~* Vulnerable populations such as children, minors, pregnant women, and intellectually challenged individuals.~* Those with cardiovascular, renal, metabolic, or chronic respiratory disease, smokers or those who have quit smoking less than 6 months ago, and those who use an inhaler to control for exercise-induced asthma.~* In addition, exclusion criteria include participants who show any signs or symptoms of COVID-19 and have had exposure to anyone with COVID-19 symptoms or any person that has tested positive for COVID-19.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No mask temperate (Type: ACTIVE_COMPARATOR): Participant exercised in room temperature environment not wearing a surgical face mask
- Mask temperate (Type: EXPERIMENTAL): Participant exercised in room temperature environment while wearing a surgical face mask
- No mask hot (Type: ACTIVE_COMPARATOR): Participant exercised in a hot environmental temperature not wearing a surgical face mask
- Mask hot (Type: EXPERIMENTAL): Participant exercised in a hot environmental temperature while wearing a surgical face mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulfate in Pregnancy and Postpartum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Severe hypertensive disorder receiving magnesium sulfate prophylaxis for less than 8 hours at birth.~Exclusion Criteria:~* Complications such as: HELLP syndrome, renal failure, eclampsia, retinal detachment, cerebral edema, pulmonary edema, hypertensive encephalopathy.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- Six Hours Postpartum (Type: EXPERIMENTAL): The woman received magnesium sulfate for 6 hours after delivery as prophylaxis to eclampsia.
- Twenty-four hours Postpartum (Type: ACTIVE_COMPARATOR): The woman received magnesium sulfate for 24 hours after delivery as prophylaxis to eclampsia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Home-Based Exercise and Weight Control Program for Pain Control in Overweight Elderly With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male \& female 50 years old~* Diagnosis of osteoarthritis by American College of Rheumatology criteria~* Knee radiographs of Kellgren and Lawrence grade 2-4~* American Arthritis Association functional class 1-3~* Body mass index of 27~Exclusion Criteria:~* Knee arthritis which did not meet American College of Rheumatology (ACR) OA criteria~* Unable to engage in exercise or follow instruction~* Limited shoulder range of motion

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Group assigned to both a Weight Control Nutritional Program and home-based exercise program (Ex+WC).
- Arm 2 (Type: ACTIVE_COMPARATOR): Group assigned to a Weight Control Nutritional Program (WC).
- Arm 3 (Type: ACTIVE_COMPARATOR): Group assigned to a home-based exercise program (Ex).
- Arm 4 (Type: NO_INTERVENTION): Usual care and non- specific health information (C).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Canrenone as Add-on in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.~Exclusion Criteria:~* diabetes mellitus~* secondary hypertension~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Canrenone 50 mg (Type: ACTIVE_COMPARATOR): Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
- Canrenone 100 mg (Type: ACTIVE_COMPARATOR): Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 18 to 60 years~2. Body mass index 20 kg/m2 to 27 kg/m2~3. Hemoglobin above 130g/L~4. Normal glucose tolerance in response to a 75g, 2-hr OGTT~Exclusion Criteria:~1. Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.~2. Any subject with active bleeding, bleeding diathesis, clotting abnormalities or recent surgery (within past 1 month)~3. Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr \> 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP \> 100 or systolic \> 180).~4. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.~5. Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.~6. Any laboratory values: AST \> 2x ULN; ALT \> 2x ULN TSH \> 6 mU/l~7. Current addiction to alcohol or substances of abuse as determined by the investigator.~8. Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation~9. Taking any prescription or non-prescription medications at the time of the study~10. Having donated blood three months prior to and three months post study procedures~11. A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded.~12. Known allergy, hypersensitivity or contraindication to receiving study medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- normal saline (Type: PLACEBO_COMPARATOR): normal saline intravenous infusion
- glucose (Type: ACTIVE_COMPARATOR): glucose intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete